Nelson Uzquiano, MD
Obstetrics · Houston, TXNPI 1316010820
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.6% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 24.3% of the total. Reporting peaked in 2023 at $269 and has fallen 78.2% since, to $59 in 2025. That places this record below the midpoint for obstetrics clinicians in TX, where the typical reported total is $1,137.
Across 48 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$242
- Astellas Pharma US Inc$178
- Mayne Pharma Commercial LLC$106
- Exeltis, USA Inc.$98
- Avion Pharmaceuticals$95
- Organon$54
- plus $224 from 8 others
Across 1 payment — averaging $32,469 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$32K
What the payments were for
- Food & beverage$90291%
- Education$949%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $242 |
| Astellas Pharma US Inc | 5 | $178 |
| Mayne Pharma Commercial LLC | 5 | $106 |
| Exeltis, USA Inc. | 5 | $98 |
| Avion Pharmaceuticals | 6 | $95 |
| Organon | 2 | $54 |
| Pfizer | 2 | $47 |
| Baxter Healthcare | 1 | $41 |
| Myovant Sciences Inc. | 2 | $34 |
| Mycovia Pharmaceuticals, Inc. | 1 | $28 |
| Mission Pharmacal Company | 2 | $23 |
| Millicent US Inc | 1 | $21 |
| Scynexis, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $13 |
How this compares
$996 in reported general payments places this provider in the 45th percentile of 85 obstetrics providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tolterodine Tartrate | 12 | $1,276 |
| Risedronate Sodium | 13 | $687 |
| Estradiol | 13 | $434 |
Paid to pharmacies, not to this prescriber.
Other obstetrics in Houston
- Sara MoufarrijHouston$52K
- Michael BalatHouston$3K
- Bridgette ParishHouston$3K
- Guy KatzHouston$1K
- Kathy SummersHouston$1K
- Emily BowdenHouston$865
- Kimberly HawkinsHouston$585
- Hearther DaleyMcAllen$57K
- Rene PerezSan Antonio$20K
- Lisa BourbeauAustin$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.